We propose that in naïve HER2-positive breast cancer cells, Ganetespib is highly effective by curbing the Hsp90 support of HER2 itself, its co-receptor EGFR and the effectors Raf, Erk1, Akt, mTOR (Fig. 5a, b)14. The gene discussed is AKT1; the disease is breast carcinoma.